Endocrinology

Cardiovascular disease

Questions discussed in this category

Is there any difference in the cardiovascular risk reduction profile of brand name Vascepa versus generic icosapent ethyl for patients with hypertriglyceridemia?

1 Answer available

What is your approach to management of hyperlipidemia in patients taking JAK inhibitors?

1 Answer available

Papers discussed in this category

N Engl J Med,

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.

Autoimmunity reviews, 2023 Dec 20

Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study.

The New England journal of medicine, 2019-01-03

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.

Related Topics in Endocrinology